HRP20211351T1 - Abx196 za upotrebu u liječenju raka mokraćnog mjehura - Google Patents

Abx196 za upotrebu u liječenju raka mokraćnog mjehura Download PDF

Info

Publication number
HRP20211351T1
HRP20211351T1 HRP20211351TT HRP20211351T HRP20211351T1 HR P20211351 T1 HRP20211351 T1 HR P20211351T1 HR P20211351T T HRP20211351T T HR P20211351TT HR P20211351 T HRP20211351 T HR P20211351T HR P20211351 T1 HRP20211351 T1 HR P20211351T1
Authority
HR
Croatia
Prior art keywords
formula
image
bladder
compound abx196
abx196
Prior art date
Application number
HRP20211351TT
Other languages
English (en)
Croatian (hr)
Inventor
Sandrine CRABE
Didier Scherrer
Hartmut Ehrlich
Philippe Pouletty
Original Assignee
Abivax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax filed Critical Abivax
Publication of HRP20211351T1 publication Critical patent/HRP20211351T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20211351TT 2017-09-13 2018-09-13 Abx196 za upotrebu u liječenju raka mokraćnog mjehura HRP20211351T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306182 2017-09-13
EP18765477.7A EP3681512B1 (en) 2017-09-13 2018-09-13 Abx196 for use in the treatment of bladder cancer
PCT/EP2018/074778 WO2019053142A1 (en) 2017-09-13 2018-09-13 ABX196 FOR USE IN THE TREATMENT OF BLADDER CANCER

Publications (1)

Publication Number Publication Date
HRP20211351T1 true HRP20211351T1 (hr) 2021-11-26

Family

ID=60001797

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211351TT HRP20211351T1 (hr) 2017-09-13 2018-09-13 Abx196 za upotrebu u liječenju raka mokraćnog mjehura

Country Status (18)

Country Link
US (1) US11266667B2 (enExample)
EP (1) EP3681512B1 (enExample)
JP (1) JP7214718B2 (enExample)
KR (1) KR102706165B1 (enExample)
CN (1) CN111182907B (enExample)
AU (1) AU2018332046B2 (enExample)
BR (1) BR112020004778A2 (enExample)
CA (1) CA3075443A1 (enExample)
CU (1) CU20200020A7 (enExample)
DK (1) DK3681512T3 (enExample)
ES (1) ES2893549T3 (enExample)
HR (1) HRP20211351T1 (enExample)
IL (1) IL273054B2 (enExample)
MX (1) MX394216B (enExample)
PL (1) PL3681512T3 (enExample)
PT (1) PT3681512T (enExample)
WO (1) WO2019053142A1 (enExample)
ZA (1) ZA202001435B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022187141A1 (en) 2021-03-01 2022-09-09 Deciduous Therapeutics Compounds for activating invariant natural killer t-cells and methods of use in eliminating inflammatory senescent cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008350531B2 (en) * 2007-12-05 2014-01-23 Abivax Use of glycosylceramides for enhancing the immune response to antigens
CN102215864A (zh) * 2008-10-08 2011-10-12 威蒂赛尔公司 用于抗流感的疫苗组合物
US9181292B2 (en) * 2011-01-05 2015-11-10 Pi-Hui Liang Methods for preparation of glycosphingolipids and uses thereof
RU2770432C2 (ru) * 2016-09-14 2022-04-18 Абивакс Комбинации для лечения рака, включающие abx196

Also Published As

Publication number Publication date
MX394216B (es) 2025-03-24
AU2018332046A1 (en) 2020-03-19
US11266667B2 (en) 2022-03-08
EP3681512A1 (en) 2020-07-22
IL273054A (en) 2020-04-30
CA3075443A1 (en) 2019-03-21
WO2019053142A1 (en) 2019-03-21
ZA202001435B (en) 2022-07-27
MX2020002812A (es) 2020-07-21
AU2018332046B2 (en) 2024-06-13
CN111182907A (zh) 2020-05-19
CN111182907B (zh) 2023-01-06
KR20200102412A (ko) 2020-08-31
IL273054B2 (en) 2023-05-01
JP2020533368A (ja) 2020-11-19
ES2893549T3 (es) 2022-02-09
JP7214718B2 (ja) 2023-01-30
BR112020004778A2 (pt) 2020-10-13
PT3681512T (pt) 2021-10-06
KR102706165B1 (ko) 2024-09-13
IL273054B1 (en) 2023-01-01
EP3681512B1 (en) 2021-08-04
PL3681512T3 (pl) 2022-01-17
CU20200020A7 (es) 2020-11-30
RU2020109889A (ru) 2021-09-06
DK3681512T3 (da) 2021-09-06
RU2020109889A3 (enExample) 2022-01-28
US20200230163A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
CN105338977B (zh) 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
IL275379B2 (en) Benzylamino-converted pyridopyrimidinones and novel antecedents as sos1 inhibitors
HRP20201681T1 (hr) Inhibitor aurora a kinaze
JP7025416B2 (ja) 好中球減少症を低減させるための組成物および方法
FI3849534T3 (fi) Yhdistelmähoidot
RU2018105655A (ru) Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака
RU2019133284A (ru) Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства
JP2016528162A5 (enExample)
WO2020102804A3 (en) Pharmaceutical combination for treatment of cancer
WO2018005519A3 (en) Cancer treatment combinations
HRP20192101T1 (hr) Inhibitori ezh2
RU2015126661A (ru) Пероральная комбинация для предотвращения и лечения патологий мочевого пузыря, органов малого таза и мочеполового аппарата
RU2017134443A (ru) Способ лечения с применением традипитанта
CN107405404A (zh) 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途
JP2018522028A5 (enExample)
JP2019513134A5 (enExample)
JP2014530181A5 (enExample)
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
PH12021552973A1 (en) Methods of treating urinary system cancers
RU2015152033A (ru) Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт
HRP20211351T1 (hr) Abx196 za upotrebu u liječenju raka mokraćnog mjehura
JP2020533368A5 (enExample)
RU2016143153A (ru) Комбинации противораковых лекарств
RU2016132400A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, имеющего противораковую активность, с гефитинибом
Das et al. Neoodjuvant imatinib mesylate for advanced primary and metastactic/recurrent gastro-intestinal stromal tumour (GIST)